Table 2.
Associations between anticholinergic therapy adherence (MMAS-8) and the studied factors
| Evaluated factor | P-value | 95% CI | OR |
|---|---|---|---|
| Age | 0.810a) | -8.03 to 10.20 | - |
| PGI-I | 0.824a) | -0.59 to 0.74 | - |
| MMSE | 0.766a) | -2.88 to 2.14 | - |
| USP SUI | 0.060a) | -0.05 to 2.27 | - |
| USP OAB | 0.151a) | -0.79 to 4.91 | - |
| USP VD | 0.562a) | -3.69 to 2.05 | - |
| USP total | 0.257a) | -1.80 to 6.50 | - |
| HAD | 0.056a) | -0.11 to 7.80 | - |
| Anxiety sub-score | 0.066a) | -0.14 to 4.33 | - |
| Depression sub-score | 0.151a) | -0.68 to 4.19 | - |
| Number of daily pills | 0.618a) | -0.29 to 0.49 | - |
| EDSS | 0.704a) | -1.20 to 1.75 | - |
| Sex | 0.800b) | - | - |
| CISC | 0.643b) | - | - |
| Botulinum toxin injection | 1.000c) | 0.10–4.62 | 0.76 |
| Side effects* | 0.022c) | 0.02–0.93 | 0.15 |
| Xerostomia | 0.222c) | - | - |
| Constipation | 0.689c) | - | - |
| Barriers | 0.058c) | - | - |
MMAS-8, Morisky Medical Adherence Scale (8-items); CI, confidence interval; OR, odds ratio; PGI-I, Patient Global Impression of Improvement; MMSE, Mini-Mental State Examination; USP, Urinary Symptom Profile; SUI, stress urinary incontinence; OAB, overactive bladder; VD, voiding dysfunction; HAD, Hospital Anxiety and Depression scale; EDSS, Expended Disability Status Scale; CISC, clean intermittent selfcatheterization.
*
Significant difference.
a)
t-test.
b)
Chi-square test.
c)
Fisher exact test.